Want to join the conversation?
$MON's FY15 ongoing EPS was $5.73, reflecting YoverY growth of 10%, which expands to 17% growth on an ongoing currency-neutral basis, driven by the performance of its Seed and Traits technology, realized licensing opportunities and strong cost discipline. On an as-reported basis, $MON's EPS was $4.81 in FY15.
Biodefense therapeutics firm $PIP announced an all-stock merger with biotech Altimmune. The respective boards of the two companies unanimously approved the merger.
$YHOO is reporting today after market close. Nobody cares about this stock.